Lifesci Capital Brokers Lift Earnings Estimates for Abivax

Key Points

• Lifesci Capital has increased its FY2025 earnings estimates for Abivax, forecasting a loss of ($3.64) per share, up from the previous estimate of ($3.68).
• Abivax has received positive ratings from various analysts, with an overall consensus rating of "Buy" and a price target averaging around $80.00.
• Institutional investors own approximately 47.91% of Abivax's shares, with significant increases in stakes from firms like GAMMA Investing LLC and Millennium Management LLC.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) - Lifesci Capital increased their FY2025 earnings estimates for Abivax in a report issued on Wednesday, July 23rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($3.64) per share for the year, up from their previous estimate of ($3.68). Lifesci Capital currently has a "Outperform" rating and a $101.00 target price on the stock. The consensus estimate for Abivax's current full-year earnings is ($2.83) per share.

Several other equities analysts also recently commented on the stock. Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Leerink Partners set a $74.00 price target on shares of Abivax and gave the company an "outperform" rating in a research note on Wednesday. JMP Securities upped their price target on shares of Abivax from $33.00 to $95.00 and gave the company a "market outperform" rating in a research note on Wednesday. Morgan Stanley raised shares of Abivax from an "equal weight" rating to an "overweight" rating and set a $71.00 price target on the stock in a research note on Wednesday. Finally, Piper Sandler upped their price target on shares of Abivax from $42.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Abivax presently has a consensus rating of "Buy" and a consensus price target of $80.00.

Abivax Trading Up 1.7%

ABVX stock opened at $69.76 on Friday. Abivax has a one year low of $4.77 and a one year high of $72.90. The company's fifty day moving average price is $9.82 and its 200-day moving average price is $7.70. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25.

Institutional Investors Weigh In On Abivax

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new position in shares of Abivax during the 4th quarter valued at about $144,000. JPMorgan Chase & Co. purchased a new stake in Abivax in the 4th quarter valued at about $5,336,000. GAMMA Investing LLC raised its holdings in Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock valued at $118,000 after buying an additional 14,855 shares during the period. Guggenheim Capital LLC purchased a new stake in Abivax in the 4th quarter valued at about $92,000. Finally, Millennium Management LLC raised its holdings in Abivax by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock valued at $6,816,000 after buying an additional 285,542 shares during the period. Institutional investors and hedge funds own 47.91% of the company's stock.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.